A5066908279- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Neurological diseases and metabolism
- Neuropeptides and Animal Physiology
- Pain Management and Placebo Effect
- Autism Spectrum Disorder Research
- Nerve injury and regeneration
- Fungal Plant Pathogen Control
- Receptor Mechanisms and Signaling
- Advanced MRI Techniques and Applications
- Nuclear Receptors and Signaling
- Plant Pathogens and Fungal Diseases
- Neurological and metabolic disorders
- RNA regulation and disease
- Alzheimer's disease research and treatments
- Medical Imaging Techniques and Applications
- Pain Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Advanced Neuroimaging Techniques and Applications
- Mycotoxins in Agriculture and Food
- Glycogen Storage Diseases and Myoclonus
University of British Columbia
2016-2025
Vancouver Coastal Health
2014-2024
Beijing YouAn Hospital
2024
Capital Medical University
2024
Canadian Sport Centre Pacific
2006-2022
Pacific Centre for Reproductive Medicine
2008-2020
Universidad Braulio Carrillo
2020
BC Innovation Council
2008-2019
Neurology, Inc
2018
Parkinson's Foundation
2018
Abstract Thirty‐four patients with advanced Parkinson's disease participated in a prospective 24‐month double‐blind, placebo‐controlled trial of fetal nigral transplantation. Patients were randomized to receive bilateral transplantation one or four donors per side placebo procedure. The primary end point was change between baseline and final visits motor component the Unified Disease Rating Scale practically defined off state. There no significant overall treatment effect ( p = 0.244)....
Abstract Objective Glial cell line–derived neurotrophic factor (GDNF) exerts potent trophic influence on midbrain dopaminergic neurons. This randomized controlled clinical trial was designed to confirm initial benefits observed in a small, open‐label using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin). Methods Thirty‐four PD patients were 1 receive bilateral continuous Ipu liatermin 15μg/putamen/day or placebo. The primary end point the change Unified Parkinson Disease...
The power of placebos has long been recognized for improving numerous medical conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism underlying placebo effect. Using ability endogenous dopamine to compete [ 11 C]raclopride binding measured by positron emission tomography, we provide in vivo evidence substantial release striatum PD patients response placebo. Our findings indicate that effect powerful and mediated through activation damaged nigrostriatal system.
Abstract Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission tomography (PET) suggested slower loss of striatal storage with compared levodopa. This prospective, 2‐year, randomized, double‐blind, multinational the rates dopamine‐terminal function de novo patients PET evidence early PD, randomized 1 to receive either or The primary outcome measure was reduction...
ABSTRACT Background Alpha‐synuclein plays a central role in the pathophysiology of Parkinson's disease. Three missense mutations SNCA , gene encoding alpha‐synuclein, as well genomic multiplications have been identified causes for autosomal‐dominantly inherited Parkinsonism. Methods Here, we describe novel mutation exon 4 H50Q substitution patient with dopa‐responsive disease family history parkinsonism and dementia. Results The variant was not observed public databases or unrelated...
Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA) neuronal loss reaches a symptomatic threshold. To explore the mechanisms functional compensation that occur in presynaptic DA nerve terminals PD, we compared striatal positron emission tomographic (PET) measurements by using [11C]dihydrotetrabenazine ([11C]DTBZ; labeling vesicular monoamine transporter type 2), [11C]methylphenidate (labeling plasma membrane transporter), and [18F]dopa (reflecting synthesis...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features manifesting LRRK2 mutation carriers generally indistinguishable from those patients with sporadic PD. However, some PD cases associated mutations lack Lewy bodies (LBs), a neuropathological hallmark We investigated whether presence or absence LBs correlates different LRRK2-related PD.We describe genetic, clinical, and findings 37 including 33...
Expectations play a central role in the mechanism of placebo effect. In Parkinson disease (PD), effect is associated with release endogenous dopamine both nigrostriatal and mesoaccumbens projections, yet factors that control this are undetermined.To determine how strength expectation clinical improvement influences degree striatal response to patients moderate PD.Randomized, repeated-measures study perceived as independent between-subjects variable.University British Columbia Hospital,...
Abstract A Saskatchewan multi-incident family was clinically characterized with Parkinson disease (PD) and Lewy body pathology. PD segregates as an autosomal-dominant trait, which could not be ascribed to any known mutation. DNA from three affected members subjected exome sequencing. Genome alignment, variant annotation comparative analyses were used identify shared coding mutations. Sanger sequencing performed within the extended ethnically matched controls. Subsequent genotyping in a...
We investigated the effects of glial cell line-derived neurotrophic factor (GDNF) in Parkinson’s disease, using intermittent intraputamenal convection-enhanced delivery via a skull-mounted transcutaneous port as novel administration paradigm to potentially afford putamen-wide therapeutic delivery. This was single-centre, randomized, double-blind, placebo-controlled trial. Patients were 35–75 years old, had motor symptoms for 5 or more years, and presented with moderate disease severity OFF...
Lack of a global consensus on the definition advanced Parkinson's disease (APD) and considerations for timing device-aided therapies may result in heterogeneity care.To reach among movement disorder specialists regarding key patient characteristics indicating transition to APD guiding appropriate use management PD symptoms.A Delphi-panel approach was utilized synthesize opinions build consensus.A panel comprised from 10 European countries with extensive experience treating patients (mean...
Abstract Background The objective of this study was to examine the effects aerobic exercise on evoked dopamine release and activity ventral striatum using positron emission tomography functional magnetic resonance imaging in Parkinson's disease (PD). Methods Thirty‐five participants were randomly allocated a 36‐session or control intervention. Each participant underwent an scan while playing reward task before after intervention determine effect anticipation reward. A subset (n = 25)...
Parkinson's disease is a progressive neurodegenerative disorder with multifactorial causes, among which genetic risk factors play part. The RAB GTPases are regulators and substrates of LRRK2, variants in the LRRK2 gene important for disease. We aimed to explore variability within cases familial